



景順證券投資信託股份有限公司
11047臺北市信義區松智路1號22樓

電話：(02)8729-9999
www.invesco.com.tw



景順證券投資信託股份有限公司 函



聯絡人：業務人員
電話：(02)8729-9852~9868

受文者：境外基金銷售機構 投資型保單客戶
組合型基金客戶 資訊合作契約客戶

發文日期：中華民國 109 年 6 月 29 日

發文字號：(109)景順字 06039 號

速 別：

密等及解密條件或保管期限：

附 件：股東英文通知信函及其中譯本

景順健康護理基金及景順亞洲平衡基金更名核准函

主旨：本公司所代理之景順盧森堡基金系列，擬修訂基金公開說明書如說明，敬請知悉。

說明：

- 一、本公司所代理之景順盧森堡基金系列，擬修訂基金公開說明書，修改之內容包含：
 - 景順健康護理基金之更名、投資目標和政策之釐清及調降管理費；
 - 景順中國基金之投資目標和政策之變更；
 - 景順亞洲平衡基金重新定位；
 - 投資目標及政策之變更，及金融衍生工具之運用
 - 更名
 - 變更總部位計算方法



景順證券投資信託股份有限公司
11047 臺北市信義區松智路1號22樓

電話：(02)8729-9999
www.invesco.com.tw

- 景順太平洋基金之投資目標及政策之釐清、計算總部位之參考投資組合之變更；
- 擺動定價機制相關揭露之更新；
- B股或有遞延銷售費用之相關變更；
- 一般修訂；
- 文件取得及額外資訊。

詳情請參閱所附股東通知信函。

二、「景順健康護理基金」及「景順亞洲平衡基金」中英文更名之申請，業於中華民國 109 年 5 月 7 日獲金融監督管理委員會以金管證投字第 1090339297 號函核准，前述二檔基金之中英文名稱變更對照表如下：

更名前中英文名稱	更名後中英文名稱	更名生效日
景順健康護理基金 Invesco Global Health Care Fund	景順健康護理創新基金 Invesco Global Health Care Innovation Fund	2020/7/29
景順亞洲平衡基金 Invesco Asia balanced Fund	景順亞洲資產配置基金 Invesco Asia Asset Allocation fund	2020/8/14

三、以上說明，敬請查照並通知 貴行各分支機構。

總經理蕭穎為



29 June 2020

Shareholder circular

Invesco Funds

Société d'Investissement à Capital Variable

Registered Office:

Vertigo Building- Polaris

2-4, rue Eugène Ruppert

L-2453 Luxembourg

R.C.S. Luxembourg B34 457

IMPORTANT: This circular is important and requires your immediate attention. If you are in any doubt as to the action you should take you should seek advice from your professional adviser/consultant.

Unless otherwise defined, all capitalised terms used herein bear the same meaning as defined in the prospectus of Invesco Funds (the "SICAV") and Appendix A (together the "Prospectus").

About the information in this circular:

The directors of the SICAV (the "Directors") and the management company of the SICAV are the persons responsible for the accuracy of the information contained in this letter. To the best of the knowledge and belief of the Directors and the management company of the SICAV (having taken all reasonable care to ensure that such is the case), the information contained in this letter is, at the date hereof, in accordance with the facts and does not omit anything likely to affect the import of such information. The Directors accept responsibility accordingly.

Invesco Funds is regulated by the Commission de Surveillance du Secteur Financier

Directors: Anne-Marie King (Irish), Rene Marston (British), Peter Carroll (Irish), Timothy Caverly (American) and Bernhard Langer (German)

Incorporated in Luxembourg No B-34457
VAT No. LU21722969

Dear Shareholder,

We are writing to you as a Shareholder of the Invesco Funds due to several amendments, as further described below, to be included in the Prospectus as of 02 July 2020 (the "Effective Date") unless otherwise stated below. All costs incurred in connection with the proposed changes below will be borne by the Management Company.

If any of the below mentioned amendments do not suit your investment requirements, you are advised that you may, at any time redeem your shares in the Funds without any redemption charges. Redemptions will be carried out in accordance with the terms of the Prospectus.

A. Change of name of the Invesco Global Health Care Fund, clarification of the investment objective and policy and reduction of management fees

From 29 July 2020, the Invesco Global Health Care Fund will be renamed Invesco Global Health Care Innovation Fund in order to better reflect the thematic investment approach. In order to be in line with the new fund's name, it will be clarified in the investment objective and policy that the Invesco Global Health Care Fund seeks to invest in innovative healthcare companies throughout the world and that the Investment Manager classifies companies as innovative based on criteria such as their products, services, processes, business models, management, use of technology or approach to serving health care needs.

In addition, and from 29 July 2020, the management fee of the Invesco Global Health Care Fund will be reduced as follows.

Share class	Existing Management Fee	New Management Fee
A	2.00%	1.50%
B	2.00%	1.50%
C	1.50%	1.00%
E	2.50%	2.25%
J	2.00%	1.50%
P/ PI	1.00%	0.75%
R	2.00%	1.50%
S	1.00%	0.75%
T	1.00%	0.75%
Z	1.00%	0.75%

For the avoidance of doubt, there is no change to the management fee in respect of "I" Share classes, as they do not bear any management fee.

For the list of Share classes available in the Invesco Global Health Care Fund, please refer to the Website of the Management Company (<http://invescomanagementcompany.lu>).

The above modifications will not change the way the Invesco Global Health Care Fund is managed nor will it result in any change to the risk profile of the Invesco Global Health Care Fund.

B. Change of the investment objective and policy of the Invesco Emerging Market Structured Equity Fund

From 29 July 2020, the investment objective and policy of the Invesco Emerging Market Structured Equity Fund will be amended in order to increase the possibility to be exposed to China A shares via shares listed on the Shanghai or Shenzhen Stock Exchanges through Stock Connect from up to 10% to up to 25% of its NAV.

This change will have no material impact on the risk profile of the Invesco Emerging Market Structured Equity Fund.

C. Change of the investment objective and policy and the relevant risks applicable, as well as change of name of the Invesco Asian Bond Fund

From 29 July 2020, the investment objective and policy of the Invesco Asian Bond Fund will be enhanced in order to allow the Invesco Asian Bond Fund to access China onshore bonds in the CIBM via Bond Connect for less than 20% of its NAV. In addition, the investment objective and policy of the Invesco Asian Bond Fund will be updated in order to allow the Invesco Asian Bond Fund to invest up to 10% of its NAV in Distressed Securities.

As a result of the changes, Bond Connect risks and Distressed Securities risk will also be applicable to the Invesco Asian Bond Fund and highlighted in the risk matrix disclosed in Section 8 (Risks Warnings) of the Prospectus.

Otherwise, the changes have no material impact on the way the Invesco Asian Bond Fund is managed nor on its risk profile.

In addition, please note that the Invesco Asian Bond Fund will be renamed the Invesco Asian Flexible Bond Fund from 29 July 2020 in order to better reflect the unconstrained nature of the Fund.

D. Change of the investment objective and policy of the Invesco PRC Equity Fund

From 29 July 2020, the investment objective and policy of the Invesco PRC Equity Fund will be amended in order to increase the possibility to be exposed to China A shares via shares listed on the Shanghai or Shenzhen Stock Exchanges through Stock Connect from up to 20% to up to 40% of its NAV. This increase of flexibility should allow the investment manager to access the full set of opportunities that exist across the Chinese market and generate alpha.

In addition and as of the Effective Date, it will be clarified that the Invesco PRC Equity Fund does not invest in UCITS and/or other UCIs with the exception of money market funds for liquidity management up to a maximum of 10% of the NAV of Invesco PRC Equity Fund.

The above changes will not have any adverse impact on the interests of existing investors and there is no change to the risk profile of the Invesco PRC Equity Fund.

E. Repositioning of the Invesco Asia Balanced Fund

E.1 – Change of investment objective and policy and use of derivatives of the Invesco Asia Balanced Fund

From 14 August 2020, the investment objective and policy of the Invesco Asia Balanced Fund will be changed with a view to reduce downward risks and volatility, stabilise risk-adjusted returns and optimise income delivery by introducing the use of a risk management overlay. Under exceptional circumstances (e.g. market crash or major crisis), the Invesco Asia Balanced Fund may be positioned defensively with up to 100% of its NAV in cash, cash equivalent, short term debt securities, other Money Market Instruments as well as other Transferable Securities, which are expected to have a low correlation to traditional equity and debt indices.

As a result of the above changes and notably the use of risk management overlay, the Invesco Asia Balanced Fund will use derivative instruments for investment purposes as well as for efficient portfolio management and hedging purposes. Such investment will however be restricted to 40% of the NAV of the Invesco Asia Balanced Fund, as measured by the commitment approach.

E.2- Change of the name of the Invesco Asia Balanced Fund

In order to better reflect the updated investment objective and policy, from 14 August 2020, the Invesco Asia Balanced Fund will be renamed Invesco Asia Asset Allocation Fund.

E.3- Change of the method of calculation of the global exposure of the Invesco Asia Balanced Fund

From 14 August 2020, the methodology used to calculate the global exposure will be amended from relative Value at Risk (VaR) to commitment approach. Following the assessment on the complexity of the Invesco Asia Balanced Fund's investment strategy and its potential exposure to derivative instruments, it is considered that the commitment approach is suitable to adequately capture the market risk of the Invesco Asia Balanced Fund.

Do any of the above amendments not suit your investment requirements?

In addition to the ability to redeem free of charge as disclosed above, you may also avail of a switch out of the Invesco Asia Balanced Fund, provided such requests are received at any time prior to 14 August 2020, into another Fund in the SICAV (subject to minimum investment amounts as set out in the Prospectus and authorisation of the particular Fund for sale in your relevant jurisdiction). The switch will be carried out in accordance with the terms of the Prospectus, but no switching fee will be imposed on any such switch. Before taking any decision to invest in another Fund, you must first refer to the Prospectus and the risks involved in relation to the same.

F. Clarification of the investment objective and change of the investment policy of the Invesco Euro Ultra-Short Term Debt Fund and Invesco USD Ultra-Short Term Debt Fund (the "Ultra-Short Term Debt Funds")

From 29 July 2020, the investment objective and policy of the Ultra-Short Term Debt Funds will be updated in order to (i) remove the reference to money market rates from the investment objective as further described below, ii) allow the use of derivative instruments for investment purposes (such investment will however be restricted to 40% of the NAV of each of the Ultra-Short Term Debt Funds, as measured by the commitment approach) and iii) change

the average portfolio duration from a maximum of 12 months to a maximum of 18 months. Further, it will be specifically clarified that the Ultra-Short Term Debt Funds, are not money market funds.

It is proposed that each of the Ultra-Short Term Debt Funds will have the below investment objective:

"The Fund seeks to achieve a positive gross return through a conservative allocation (low duration and high credit quality) to rates and credit as more fully described below. Due to the prevailing interest rate environment or other factors, it is possible that this may not be achieved."

The above changes will not materially prejudice the rights or interests of existing investors and will not materially impact the way the Ultra-Short Term Debt Funds are managed. The change of average portfolio duration from a maximum of 12 months to a maximum of 18 months could have an impact on the risk profile of the Ultra-Short Term Debt Funds due to increased sensitivity of the Ultra-Short Term Debt Funds to movement in interest rates when they take the flexibility to have average portfolio duration out to 18 months.

G. Clarification of the investment objective and policy and change of the benchmark to measure the global exposure of the Invesco Pacific Equity Fund

From the Effective Date, the definition of "Asia Pacific region" within the investment objective and policy of the Invesco Pacific Equity Fund will be amended by adding an explicit reference to India to better reflect the way the Invesco Pacific Equity Fund is being managed.

The investment management team of the Invesco Pacific Equity Fund has historically included investment in India as a part of its "Asia Pacific region" investment universe, which is expected to continue as a part of the long-term strategy. While the investment policy has always allowed this as part of the 30% other component we believe it is more transparent to include India in the definition of "Asia Pacific region" and hence the primary allocation as it is and has been a country that the team has invested in systematically for many years.

The Invesco Pacific Equity Fund uses the relative Value-at-Risk approach in order to measure its global exposure by reference to MSCI AC Pacific Index. From the Effective Date, the benchmark to measure the global exposure of the Invesco Pacific Equity Fund will change to MSCI AC Asia Pacific Index, which includes India and will therefore be aligned with the clarification of its investment objective and policy.

The above modifications will not change the way the Invesco Pacific Equity Fund is managed nor will it result in any change to the risk profile of the Invesco Pacific Equity Fund.

H. Clarification of the investment objective and policy of the Invesco Macro Allocation Strategy Fund

From the Effective Date, the investment objective and policy of the Invesco Macro Allocation Strategy Fund will be amended to better reflect the current investment practice with regards to a strategy which will help shield the portfolio in an equity sell off environment.

Therefore, it will be clarified that the Invesco Macro Allocation Strategy Fund may gain exposure to equities either directly or through the use of financial derivative instruments, which may include a factor allocation strategy. Any short exposure will be taken via the use of financial derivative instruments.

The above modifications will not change the way the Invesco Macro Allocation Strategy Fund is managed nor will it result in any change to the risk profile of the Invesco Macro Allocation Strategy Fund.

I. Reduction of the Management fee of the E Share class for various Funds

From the Effective Date, the management fee of the E Shares of the Funds listed below will be reduced in order to maximise the investment outcome for clients and competitiveness, as follows:

Fund	Existing Management Fee of the E Share	New Management Fee of the E Share
Invesco Global Real Estate Securities Fund	2.25%	1.95%
Invesco Continental European Equity Fund	2.25%	2.00%
Invesco Japanese Equity Core Fund	2.25%	2.00%
Invesco UK Equity Fund	2.25%	2.00%
Invesco US Value Equity Fund	2.25%	2.00%
Invesco Energy Fund	2.25%	2.00%
Invesco Global Equity Income Fund	2.25%	2.00%
Invesco US Equity Fund	2.25%	2.00%

For the list of Share classes available in the Funds listed above, please refer to the Website of the Management Company (<http://invescomanagementcompany.lu>).

J. Update to disclosures regarding swing pricing mechanism

The Board of Directors has taken the decision to update the disclosures regarding swing pricing mechanism as disclosed in Section 6.2 (Calculation of assets and liabilities) of the prospectus to allow the adjustment applicable to a specific Fund to exceed 2% of the original NAV per Share on a temporary basis under exceptional market conditions (such as high market volatility) (i) where it is believed that the price adjustment limit of 2% currently stated in the prospectus does not adequately reflect the disconnect between prices used in the NAV calculation and the dealing and other costs and (ii) where justified by the best interest of Shareholders. When this happens investors will be given prior notice on the Website of the Management Company.

K. Change in relation to the CDSC for the B Share classes

From the Effective Date, the wording in relation to the CDSC of the B Share classes will be changed in order to state a maximum rate of CDSC while the actual rate for the relevant Fund will be set out in the annual report and on the Website of the Management Company where it deviates from the maximum.

For the avoidance of doubt there will be no change in the fee level or cost in managing the relevant Funds.

L. General Amendments

From the Effective Date, in Section 1 of the Prospectus, "Important Information for Resident Indians / Non-resident Indians / Overseas Citizens of India" will be added to cover the selling restrictions applicable to Indian investors.

M. Availability of documents and additional information

Do you require additional information?

The updated Prospectus, its Appendix A and the updated Key Investor Information Documents will be available free of charge at the registered office of the SICAV. These will also be available from the website of the Management Company of the SICAV (Invesco Management S.A.) as of the Effective Date:
<http://www.invescomanagementcompany.lu>.

Do you have any queries in relation to the above? Or would you like information on other products in the Invesco range of funds that are authorised for sale in your jurisdiction? Please contact your local Invesco office.

You may contact

- Germany: Invesco Asset Management Deutschland GmbH at (+49) 69 29807 0,
- Austria: Invesco Asset Management Österreich- Zweigniederlassung der Invesco Asset Management Deutschland GmbH at (+43) 1 316 2000,
- Ireland: Invesco Investment Management Limited at (+353) 1 439 8000,
- Hong Kong: Invesco Hong Kong Limited at (+852) 3191 8282,
- Spain: Invesco Asset Management S.A. Sucursal en España at (+34) 91 781 3020,
- Belgium: Invesco Asset Management S.A. Belgian Branch at (+32) 2 641 01 70,
- France: Invesco Asset Management S.A. at (+33) 1 56 62 43 00,
- Italy: Invesco Asset Management S.A. Sede Secondaria, at (+39) 02 88074.1,
- Switzerland: Invesco Asset Management (Schweiz) AG at (+41) 44 287 9000,
- Netherlands: Invesco Asset Management SA Dutch Branch at (+31) 205 61 62 61,
- Sweden: Invesco Asset Management S.A (France) Swedish Filial at (+46) 8 463 11 06
- United Kingdom: Invesco Global Investment Funds Limited at (+44) 0 1491 417 000.

N. Further information

The value of investments and the income generated from investment can fluctuate (this may partly be the result of exchange rate fluctuations). Investors may not get back the full amount invested.

For Shareholders In Germany: If you are acting as a distributor for German clients, please be advised you are not required to forward this circular to your end clients by durable media.

For Shareholders In Switzerland: The Prospectus, the Key Investor Information Documents and the Articles, as well as the annual and interim reports of the Invesco Funds may be obtained free of charge from the Swiss representative. Invesco Asset Management (Switzerland) Ltd., Talacker 34, 8001 Zurich, is the Swiss representative and BNP Paribas Securities Services, Paris, Succursale de Zurich, Selnaustrasse 16, 8002 Zurich, is the Swiss paying agent.

For Shareholders in Italy: Redemptions requests will be carried out in accordance with the terms of the Prospectus. Shareholders will be able to redeem without any redemption charges other than the intermediation fee applied by the relevant paying agents in Italy, as disclosed in the Annex to the Italian application form in force and available on the website www.invesco.it.

A copy of this letter is available in various languages. For further information, please contact the Investor Services Team, IFDS, Dublin on (+353) 1 439 8100 (option 2) or your local Invesco office.

Thank you for taking the time to read this communication.

Yours faithfully,

A handwritten signature in black ink, appearing to be 'N. El' or similar, written in a cursive style.

By order of the Board of Directors

Acknowledged by Invesco Management S.A.



景順盧森堡基金系列
可變資本投資公司 (SICAV)
Vertigo Building- Polaris
2-4, rue Eugène Ruppert
L-2453 Luxembourg
R.C.S. Luxembourg B34 457

2020 年 6 月 29 日

股東通知函：

本通知函為重要文件，請您立即處理。若您對於應採取之行動有任何疑問，請諮詢您的專業顧問。

除本通知函另有定義外，本文用語之意義均與景順盧森堡基金系列（下稱 SICAV）公開說明書及附錄 A（以下合稱「公開說明書」）中之定義相同。

關於本通知函所載資訊：

SICAV 之董事（下稱「董事」）及管理公司對於本信函所載資訊之正確性負責。就 SICAV 之董事及管理公司所深知及確信（已採取一切合理注意以確保所述情況如實），本通知函所載資訊與本函發函日之事實相符，並無遺漏任何事實以致可能影響該等資訊之涵義。董事就此承擔責任。

景順盧森堡基金系列受盧森堡金融業監督委員會的監管

董事：

Anne-Marie King (愛爾蘭)、Rene Marston (英國)、Peter Carroll (愛爾蘭)、Timothy Caverly (美國) 及 Bernhard Langer (德國)

於盧森堡註冊 編號 B-34457
VAT No. LU21722969



致股東：

本函旨在通知景順盧森堡基金系列之股東若干修訂，詳情如後所述。除下述另有記載外，此等修訂將載於 2020 年 7 月 2 日（下稱「生效日」）之公開說明書。因下述修訂而衍生之所有費用將由管理公司負擔。

若下述任何修訂不符您的投資要求，建議您得隨時贖回本基金之股份且無需支付贖回費。贖回將依公開說明書之條款進行。

A. 景順健康護理基金之更名、投資目標和政策之釐清及調降管理費

自 2020 年 7 月 29 日起，為了更好地反映主題投資方法，景順健康護理基金將更名為景順健康護理創新基金。為與新名稱維持一致，將於投資目標及政策中說明景順健康護理基金尋求投資於全球健康護理創新公司，以及投資經理係根據公司的產品、服務、流程、業務模型、管理、技術使用或滿足醫療保健需求的方法等標準將公司歸類為創新公司。

此外，自 2020 年 7 月 29 日起，景順健康護理基金之管理費將調降如下：

基金級別	現行管理費	更新後管理費
A	2.00%	1.50%
B	2.00%	1.50%
C	1.50%	1.00%

關於景順健康護理基金現有基金級別之表單，詳至管理公司網站（<http://invescomanagementcompany.lu>）。

上述修訂不會變更景順健康護理基金之管理方式或導致景順健康護理基金之風險概況之任何變更。

B. 景順中國基金之投資目標和政策之變更

自 2020 年 7 月 29 日起，將修改景順中國基金的投資目標和政策，可將其資產淨值最多 40%（原為最多 20% 資產淨值的）以透過互聯互通投資於在上海或深圳證券交易所上市的股票而增加投資中國 A 股部位的可能性。此靈活性的提高將使投資經理可以利用整個中國市場存在的所有機會並締造超額回報。

此外，自生效日起，茲澄清景順中國基金不投資於 UCITS 和/或其他 UCI（但用於流動性管理的貨幣市場基金除外，惟最高不超過景順中國基金資產淨值的 10%）。

上述變更不會對現有投資人的利益造成任何不利影響，且景順中國基金的風險概況也不會變更。

C. 景順亞洲平衡基金重新定位(repositioning)

C.1 - 景順亞洲平衡基金之投資目標及政策之變更，及金融衍生工具之運用

自 2020 年 8 月 14 日起，將變更景順亞洲平衡基金之投資目標及政策，利用引進風險管理覆蓋之使用以降低下行風險及波動、穩定風險調整報酬及優化收益分配。在例外情況下（如市場崩盤或大型危機），景順亞洲平衡基金可防禦性地調整部位，將資產淨值之最多 100% 投資於預期與傳統股票及債務指數具較低關聯性之現金、現金等價物、短期債務證券、其他貨幣市場工具及其他可轉讓證券。

基於上述變動，特別是運用風險管理配置，景順亞洲平衡基金將為了投資目的、有效管理投資組合及避險之目的，使用金融衍生工具。但該投資將限於景順亞洲平衡基金以承諾法計算之資產淨值之 40%。

C.2 - 景順亞洲平衡基金之更名



為反映變更後之投資目標及政策，自 2020 年 8 月 14 日起，景順亞洲平衡基金之名稱將變更為景順亞洲資產配置基金。

C.3 - 景順亞洲平衡基金變更總部位計算方法

自 2020 年 7 月 29 日起，計算總部位之方法將自相對風險值法變更為承諾法。於評估景順亞洲平衡基金投資策略及其衍生性金融商品潛在曝險之複雜性後，認為承諾法適合充分捕捉景順亞洲平衡基金之市場風險。

是否上述任何修訂不符您的投資要求？

股東除了可以無需支付贖回費進行贖回外（如上述），您亦可選擇隨時將景順亞洲平衡基金轉換至 SICAV 下之其他子基金，惟此要求必須於 2020 年 8 月 14 日前收到（仍須遵守公開說明書所載之最低投資金額，並取決於特定基金是否獲准於您所在之相關司法轄區內銷售）。該等轉換將依據該公開說明書之條款執行，但任何此等轉換均無需支付轉換費用。決定投資其他基金之前，您應先參閱該基金之公開說明書及其所涉風險。

D. 景順太平洋基金之投資標的及政策之釐清、計算總部位之參考投資組合之變更

從生效日起，景順太平洋基金的投資目標和政策中所載「亞太區」的定義將變更，明確新增印度，以更好地反映景順太平洋基金的管理方式。

景順太平洋基金的投資管理團隊過去已將對印度的投資納入其亞太區投資領域的一部分，此將持續作為長期策略的一部分。儘管投資政策向來允許將其作為其他 30% 組成部分的一部分，但我們認為將印度涵括於「亞太區」之定義及主要配置內是更透明的，因為團隊多年來一直系統性地投資於印度。

景順太平洋基金採用相對風險值法，以 MSCI AC Pacific Index 指數來衡量其總部位。從生效日起，衡量景順太平洋基金總部位的參考投資組合將變更為包括印度的 MSCI AC Asia Pacific Index 指數，因此將與釐清後之投資目標和政策保持一致。

上述修訂不會變更景順太平洋基金之管理方式或導致景順太平洋基金之風險概況之任何變更。

E. 擺動定價機制相關揭露之更新

董事會已作成決定，更新公開說明書第 6.2 節（計算資產與負債）中有關擺動定價機制之揭露，倘若(i)最新公開說明書中所述價格調整之 2% 限制，被認為未能充分反映計算資產淨值之價格與交易及其他費用之脫節，且(ii)係為符合股東最大利益而被視為正當時，在特殊的市場條件（例如市場大幅波動）下，允許適用於特定基金的調整可暫時性地超過原始每股資產淨值的 2%。發生此種情況時，將在管理公司的網站上對投資人為事前通知。

F. B 股或有遞延銷售費用之相關變更

自生效日起，將變更與 B 股的或有遞延銷售費用(CDSC)相關的描述，以說明 CDSC 之最高費率，而相關基金的實際費用比率與上限比率不同，將載於年度報告和管理公司網站。

為避免疑義，管理相關基金的費用水平或成本不會變更。

G. 一般修訂

自生效日起，公開說明書第 1 章將新增「有關印度居民/非印度居民/印度海外公民的重要資訊」，以涵蓋適用於印度投資人的銷售限制。



H. 文件取得及額外資訊

您需要額外資訊？

更新後之公開說明書、附錄 A 及更新後之重要投資者資訊文件得於 SICAV 之註冊辦公室免費索取，亦可於生效日起在 SICAV 的管理公司 (Invesco Management S.A.) 網站 <http://www.invescomanagementcompany.lu> 取得。

您對上述說明是否有任何疑問？或您想要取得您所在司法管轄權區經核准銷售的景順系列基金的其他產品資訊？請聯繫當地的景順辦事處。

您可以聯繫

- 台灣：景順證券投資信託股份有限公司 (電話：(+886) 0800 045 066)
- 德國：Invesco Asset Management Deutschland GmbH at (+49) 69 29807 0,
- 奧地利：Invesco Asset Management Österreich- Zweigniederlassung der Invesco Asset Management Deutschland GmbH at (+43) 1 316 2000,
- 愛爾蘭：Invesco Investment Management Limited at (+353) 1 439 8000,
- 香港：Invesco Hong Kong Limited at (+852) 3191 8282,
- 西班牙：Invesco Asset Management S.A. Sucursal en España at (+34) 91 781 3020,
- 比利時：Invesco Asset Management S.A. Belgian Branch at (+32) 2 641 01 70,
- 法國：Invesco Asset Management S.A. at (+33) 1 56 62 43 00,
- 義大利：Invesco Asset Management S.A. Sede Secondaria, at (+39) 02 88074.1,
- 瑞士：Invesco Asset Management (Schweiz) AG at (+41) 44 287 9000,
- 荷蘭：Invesco Asset Management SA Dutch Branch at (+31) 205 61 62 61,
- 瑞典：Invesco Asset Management S.A (France) Swedish Filial at (+46) 8 463 11 06
- 英國：Invesco Global Investment Funds Limited at (+44) 0 1491 417 000.

I. 其他資訊

投資價值及投資產生的收入或會波動（可能部分受匯率波動所致），投資人未必能收回全部已投資金額。

- **致德國股東：**如您為代表德國客戶行事之經銷商，則您無需透過持久性媒介向終端客戶寄送本信函。
- **致瑞士股東：**瑞士股東可向瑞士代表免費索取公開說明書、重要投資者資訊文件、章程以及景順基金的年報及中期報告。瑞士代表為 Invesco Asset Management (Switzerland) Ltd.，地址為 Talacker 34, 8001 Zurich，以及瑞士付款代理為 BNP Paribas Securities Services, Paris，地址為 Succursale de Zurich, Selnaustrasse 16, 8002 Zurich。
- **致義大利股東：**贖回請求將依公開說明書條款進行。除支付予相關義大利付款代理之中介費外，股東得贖回且無需支付任何贖回費，如義大利申請表格之附件中所載，該表格可於網站 www.invesco.it 取得。

本信函有多種語言版本。請聯繫都柏林投資人服務團隊 IFDS (電話：(+353) 1 439 8100) (選項 2) 或您所在地的景順辦事處以取得更多資訊。

感謝您抽出寶貴時間閱讀本信函。

承董事會命

經 Invesco Management S.A. 確認

檔 號：
保存年限：

金融監督管理委員會 函

地址：22041新北市板橋區縣民大道2段7號1
8樓

承辦人：蘇郁如

電話：02-8773-5100分機7422

傳真：02-8773-4154

受文者：景順證券投資信託股份有限公司（代表人潘新江先生）

發文日期：中華民國109年5月7日

發文字號：金管證投字第1090339297號

速別：普通件

密等及解密條件或保密期限：

附件：

主旨：所請貴公司總代理之「景順健康護理基金」等2檔境外基金變更基金中英文名稱一案，同意照辦，請查照。

說明：

- 一、依據境外基金管理辦法第12條第6項規定及貴公司109年4月10日景順字第202004006號函辦理。
- 二、核准景順盧森堡基金系列之子基金「景順健康護理基金（Invesco Global Health Care Fund）」變更中英文名稱為「景順健康護理創新基金（Invesco Global Health Care Innovation Fund）」，「景順亞洲平衡基金（Invesco Asia Balanced Fund）」變更中英文名稱為「景順亞洲資產配置基金（Invesco Asia Asset Allocation Fund）」。
- 三、自基金名稱變更之日起1年內，請於投資人須知及公開說明書中譯本並列基金之新舊名稱。
- 四、貴公司及銷售機構應將更名情事通知投資人。
- 五、貴公司應依境外基金管理辦法第12條第6項規定，於事實發生日起3日內經由本會指定之資訊傳輸系統（www.fundcl

電子
文
騎

6

ear.com.tw) 辦理公告，並將修正後之公開說明書中譯本及投資人須知，依前揭辦法第37條及第39條之規定於修正後3日內辦理公告。

六、旨揭基金變更事宜尚須經註冊地主管機關核准，若該等主管機關嗣後有未同意旨揭變更事項之情事，請儘速向本會申報。

正本：景順證券投資信託股份有限公司（代表人潘新江先生）

副本：中華民國證券投資信託暨顧問商業同業公會（代表人張錫先生）、臺灣集中保管結算所股份有限公司（代表人林修銘先生）、中央銀行外匯局

2020/05/07
17:28:04

裝



訂

